|
SkinMedica Closes $15 million Round of Financing
04/05/2005
April 5, 2005 - SkinMedica, Inc., a specialty pharmaceutical company
developing and marketing dermatology products, announced today the closing of a
$15 million private placement of its Series E preferred stock. EuclidSR
Partners, a new investor, led the round and existing investors Apax Partners,
Domain Associates, HealthCare Ventures, Montreux Equity Partners, Perseus-Soros
BioPharmaceutical Fund and St. Paul Venture Capital also participated.
Concurrent with the investment, Graham D.S. Anderson, General Partner,
EuclidSR Partners joins SkinMedica’s Board of Directors. Mr. Anderson has served
in several professional capacities in management, consulting, law, software and
Internet enterprises. Prior to joining EuclidSR Partners in 1996, he was a
consultant to AOL, Image Technology Corporation, CI Impressions, Inc. and The
Walt Disney Company. Previously, he practiced law at Susman Godfrey LLP where he
concentrated on securities, private equity and software law. He is a CFA
Charterholder and graduate of Yale College, the University of Glasgow and the
Yale Law School.
About SkinMedica
SkinMedica is a privately held specialty pharmaceutical company marketing
both prescription and cosmeceutical dermatology products. SkinMedica’s EpiQuin
Micro (4% hydroquinone) treats melasma and postinflammatory hyperpigmentation,
and VANIQA (eflornithine hydrochloride) Cream, 13.9% is the only FDA-approved
prescription product for the treatment of unwanted facial hair in women. The
company’s full line of cosmeceutical products, which is sold through physicians,
includes TNS Recovery Complex with NouriCel-MD to help improve the health and
appearance of aging skin. SkinMedica is based in Carlsbad, California. For
information, visit: www.skinmedica.com.
|
